Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine

Transplantation

Volumn 74, Issue 8, 2002, Pages 1070-1076

  Flechner, Stuart M ^a   Goldfarb, David ^a   Modlin, Charles ^a   Feng, Jingyuan ^a   Krishnamurthi, Venkatesh ^a   Mastroianni, Barbara ^a   Savas, Kathy ^a   Cook, Daniel J ^a   Novick, Andrew C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTILIPEMIC AGENT; ANTIVIRUS AGENT; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; GANCICLOVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID;

ABDOMINAL PAIN; ADULT; AGED; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DEHYDRATION; DRUG BLOOD LEVEL; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; WOUND INFECTION;

EID: 0037184316     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200210270-00002     Document Type: Article

References (30)

1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996 [comments]. N Engl J Med 2000; 342(9): 605-612.
2. Ciancio G, Miller A, Burke GW, et al. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. Transplant Proc 2001; 33(1-2): 1013-1014.
3. Ponticelli C. Progression of renal damage in chronic rejection. Kidney Int 2000; 57 (suppl 75): S62-S70.
4. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55(4): 752-757.
5. Lindholm A, Ohlman S, Albrechtsen D, et al. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993; 56(2): 307-315.
6. Flechner SM, Modlin CS, Serrano DP, et al. Determinants of chronic renal allograft rejection in cyclosporine treated patients. Transplantation 1996; 62(9): 1235-1241.
7. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35(2): 333-346.
8. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31(5): 335-340.
9. Flechner SM, Avery RK, Fisher R, et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998; 66(12): 1682-1688.
10. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55(2): 713-723.
11. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2(8104-8105): 1323-1327.
12. Flechner SM, Van Buren C, Kerman R, et al. The nephrotoxicity of cyclosporine in renal transplant recipients. Transplant Proc 1983; 15: 2689-2694.
13. Ong AC, Fine LG. Loss of glomerular function and tubulointerstitial fibrosis: Cause or effect? Kidney Int 1994; 45(2): 345-351.
14. Falkenhain ME, Cosio FG, Sedmak DD. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996; 62(3): 364-370.
15. Goldstein DJ, Zuech N, Sehgal V, et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: Incidence and progression. Transplantation 1997; 63(5): 664-668.
16. Jain A, Reyes J, Kashyap R, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 1999; 230(3): 441-449.
17. Almond PS, Gillingham KJ, Sibley R, et al. Renal transplant function after ten years of cyclosporine. Transplantation 1992; 53(2): 316-323.
18. Burke JF, Pirsch JD, Ramos EL, et al. Long-term efficacy and safety of cyclosporine in renal-transplant recipients [comments]. N Engl J Med 1994; 331(6): 358-363.
19. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group [comments]. Lancet 2000; 356(9225): 194-202.
20. McAlister VC, Gao Z, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355(9201): 376-377.
21. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71(2): 271-280.
22. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 79(5): 777-786.
23. Andoh TF, Lindsley J, Franceschini N, et al. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model [comments]. Transplantation 1996; 62(3): 311-316.
24. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group [comments]. Transplantation 1999; 67(7): 1036-1042.
25. Allison A. The immunosuppressive actions of mycophenolic acid. Immunol Rev 1993; 136: 1.
26. Vu MD, Qi S, Xu D, et al. Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 1998; 66(12): 1575-1580.
27. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients: U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225-232.
28. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69(7): 1252-1260.
29. Satterthwaite R, Aswad S, Sunga V, et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 1998; 65(3): 446-449.
30. Li Y, Zheng XX, Li XC, et al. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66(10): 1387-1388.